Medical World News® After Hours: Thoracic Medical Oncologist Inga Lennes, MD, MBA, MPH, on Healthy Eating

Video

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

For this installment of After Hours from the Medical World News® broadcast, CancerNetwork® sat down with Inga Lennes, MD, MBA, MPH, to talk about her love of cooking, healthy eating, and her personal Instagram, @IngaKitchen, where she posts photos of her latest recipes.

She says cooking offers her an opportunity to shift gears after a long day at work as well as provide nourishing food for her family, making this a hobby that’s easy to stick to. She also shared some words of wisdom about staying on track with healthy eating and having motivation to cook meals on a busy schedule.

Recent Videos
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Related Content